PM
CRBP icon

Prosight Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Prosight Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.1M Sell
650,000
-47,108
-7% -$446K 1.05% 20
2026
Q1 		$6.55M Buy
697,108
+13,236
+2% +$111K 1.07% 22
2025
Q4 		$5.57M Buy
683,872
+340,472
+99% +$4.2M 1.15% 25
2025
Q3 		$4.34M Sell
343,400
-236,493
-41% -$2.25M 1.01% 27
2025
Q2 		$4M Buy
579,893
+4,757
+0.8% +$34.6K 0.98% 27
2025
Q1 		$3.05M Buy
575,136
+305,136
+113% +$2.69M 1% 26
2024
Q4 		$3.19M Buy
270,000
+140,000
+108% +$2.35M 0.88% 28
2024
Q3 		$2.68M Buy
+130,000
New +$6.65M 0.66% 34
2024
Q2 		– Sell
-100,617
Closed -$3.95M – 50
2024
Q1 		$3.95M Buy
+100,617
New +$2.48M 1.1% 25

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Prosight Management's CRBP Position: Q2 2026 in Review

Prosight Management reduced its Corbus Pharmaceuticals (CRBP) stake by 6.8% in Q2 2026, selling an estimated $446K and leaving 650,000 shares worth $6.1M. The position accounts for 1.05% of the portfolio, ranked #20.

Prosight Management first reported a position in CRBP in Q1 2024 and has held it in 9 quarters since. The position peaked at $6.55M in Q1 2026. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Prosight Management held 650,000 shares of Corbus Pharmaceuticals worth $6.1M as of Q2 2026.
  • Prosight Management sold 47,108 Corbus Pharmaceuticals shares in Q2 2026, an estimated $446K.
  • Corbus Pharmaceuticals made up 1.05% of Prosight Management's portfolio in Q2 2026, its #20 holding.
  • Prosight Management first reported a position in Corbus Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • Prosight Management's Corbus Pharmaceuticals position peaked at $6.55M in Q1 2026.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.